Campbell David Alan 4
4 · Janux Therapeutics, Inc. · Filed Jan 2, 2026
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2026-01-02$13.73/sh−8,072$110,829→ 284,982 total - Award
Common Stock
2026-01-02+96,600→ 381,582 total - Award
Stock option (right to buy)
2026-01-02+338,100→ 338,100 totalExercise: $13.65Exp: 2036-01-01→ Common Stock (338,100 underlying)
Footnotes (3)
- [F1]The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- [F2]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
- [F3]25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.